Macupatide

Macupatide (LY3532226) is Eli Lilly's once-weekly long-acting GIP receptor agonist in Phase 2 for obesity and type 2 diabetes, paired in most Lilly trials with the selective amylin receptor agonist eloralintide (LY3841136) [1][2]. Macupatide is a standalone GIPR agonist, not an amylin analog, which places it mechanistically closer to the GIP arm of tirzepatide (Mounjaro/Zepbound) than to Novo Nordisk's cagrilintide. The combination with eloralintide is therefore a GIP plus amylin stack, mechanistically distinct from both CagriSema (amylin plus GLP-1) and tirzepatide alone (GIP plus GLP-1). This is Lilly's next metabolic bet after tirzepatide delivered more than $16B in 2024 and reset the obesity drug market [6]. The core investor question is whether a standalone GIPR agonist stacked with amylin can beat tirzepatide monotherapy, since tirzepatide already delivers GIP receptor activation alongside GLP-1. If Lilly succeeds, macupatide plus eloralintide becomes a post-tirzepatide combination with a fresh IP runway beyond tirzepatide's 2036 composition-of-matter patent cliff [10]. If not, the combination has little commercial lane because tirzepatide already covers the GIP mechanism. Phase 2 topline data in 2026 and 2027 will decide which outcome prevails.

Phase 2 across three active trials, with Lilly disclosure in both 2025 and 2026 10-K filings [5][6]. NCT07215559 is the lead combination study with eloralintide in T2D plus obesity (n=200, recruiting per ClinicalTrials.gov), evaluating macupatide monotherapy, eloralintide monotherapy, and the combination against placebo [2]. NCT07589608 extends the design to obesity-only patients (n=400, recruiting) [3]. NCT06143956 is the LY900038 master protocol platform study with intervention-specific appendices covering macupatide, eloralintide, and other Lilly obesity assets (n=1,481, recruiting) [4]. A fourth planned study, NCT07765511, was a Japanese safety, PK, and PD study of macupatide monotherapy and macupatide plus eloralintide in obesity without T2D; Lilly withdrew it before first enrollment per ClinicalTrials.gov (last update 2026-08-14), signaling focus on the main global dose-ranging program [8]. No FDA designations (no breakthrough or fast track) because Lilly has not yet published efficacy data to anchor a filing. Phase 1b data in Diabetes, Obesity and Metabolism (2026) showed macupatide alone or combined with dulaglutide improved insulin sensitivity and beta cell function in T2D patients, consistent with chronic GIP receptor activation [1]. First Phase 2 toplines are plausible in late 2026 through 2027. Expected lead readout: 2027-Q2 pending Lilly's cadence, with Phase 3 initiation contingent on dose-response data from the master protocol.

GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone released from K cells in the proximal small intestine within minutes of eating. It amplifies glucose-dependent insulin secretion from pancreatic beta cells, modulates glucagon release, acts on adipose tissue to influence fat storage and metabolism, and signals the central nervous system to influence appetite and body weight. In type 2 diabetes the acute insulinotropic effect of GIP is blunted, but chronic pharmacologic GIP receptor activation appears to restore insulin sensitivity and beta cell function. This matches the Phase 1b data from Heise et al. 2026, which showed macupatide alone or on top of dulaglutide improved insulin sensitivity and beta cell function in T2D patients [1]. Macupatide is a long-acting peptide engineered for once-weekly subcutaneous dosing at the GIP receptor, a class B G protein-coupled receptor. Mechanism validation at the GIP receptor level is strong because tirzepatide, Lilly's own dual GIP and GLP-1 receptor agonist, is already approved and delivered more than $16B in 2024, confirming that chronic GIP receptor activation combined with GLP-1 agonism drives durable weight loss [6]. However, no standalone GIPR agonist has been approved, so macupatide monotherapy is a first-in-class readout. Eloralintide (LY3841136) is a separate molecule: a selective amylin receptor 1 (AMY1R) agonist. The macupatide plus eloralintide combination therefore hits GIP biology from macupatide and amylin biology from eloralintide, which is mechanistically distinct from CagriSema (amylin plus GLP-1) and from tirzepatide (GIP plus GLP-1) [2]. The open scientific question is whether a standalone GIPR agonist adds anything meaningful on top of amylin agonism given that tirzepatide already activates GIP receptors as half of a dual agonist. Lilly's apparent strategic answer is that standalone GIPR activation gives dose-ratio flexibility unavailable in a fixed-ratio dual agonist like tirzepatide, plus a fresh IP runway beyond tirzepatide's 2036 patent cliff [10].

NCT07215559 randomizes 200 adults with obesity or overweight plus T2D to macupatide monotherapy, eloralintide monotherapy, or combinations, with percent change from baseline body weight as the primary endpoint [2]. ClinicalTrials.gov currently lists the trial as recruiting rather than active-not-recruiting, which pushes the data cut toward late 2027 rather than 2026, since enrollment of 200 participants followed by a 26 to 52 week dosing window takes time. NCT07589608 mirrors the design in a 400-patient obesity-only population, letting Lilly separate the T2D glycemic effect from pure weight-loss biology [3]. NCT06143956 is the LY900038 master protocol, a 1,481-patient platform study with multiple intervention-specific appendices covering Lilly's broader obesity pipeline including macupatide and eloralintide arms [4]. The design is standard for modern obesity trials: percent weight loss at 26 or 52 weeks, placebo-controlled, dose-ranging, with no active comparator against tirzepatide or semaglutide yet. The read-across to tirzepatide is implicit rather than explicit, which keeps commercial comparisons indirect until Phase 3. Combined enrollment of roughly 2,081 patients across the three active Phase 2 trials signals Lilly is willing to spend heavily on dose-response characterization before committing to a Phase 3 budget, consistent with how they ran the tirzepatide program. The withdrawn Japanese bridging study (NCT07765511) was never on the pivotal path [8].

Our model estimates a 15% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 35%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by the sponsor's strong record of getting drugs approved and larger-than-typical enrollment for this phase; it is held back by weak or limited earlier-phase results and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the main story. Macupatide is a standalone GIPR agonist, so the commercial pitch depends on either monotherapy weight loss that beats historical GIP-only benchmarks (there is no approved standalone GIPR agonist to anchor expectations) or on the GIP plus amylin combination with eloralintide outperforming tirzepatide monotherapy by a clinically meaningful margin. The mechanistic hurdle is real: tirzepatide already activates GIP receptors as half of its dual mechanism, so macupatide must prove that solo GIP activation stacked with amylin outperforms GIP plus GLP-1 in a single molecule. On the amylin side of the combination, the current benchmark is Zealand Pharma's petrelintide, which in the ZUPREME-1 Phase 2 trial delivered up to 10.7% weight loss at 42 weeks in obesity without T2D and up to 9.2% in ZUPREME-2 with T2D, with placebo-like GI tolerability and no vomiting or GI-driven discontinuations at the maximally effective dose [9]. If eloralintide (Lilly's amylin partner for macupatide) cannot match that bar, the combination narrative weakens. Safety risk centers on GI tolerability. GIP receptor agonism alone appears better tolerated than GLP-1 agonism in isolation (based on tirzepatide pharmacology), but adding amylin agonism via eloralintide reintroduces nausea and gastric-emptying effects that can compound with GIP effects on satiety. Execution risk is low. Lilly runs clinical operations at a level few sponsors match, and three parallel Phase 2 trials covering more than 2,000 patients means the dose-response granularity will be strong [2][3][4]. Commercial risk is significant. Payers are already pushing back on GLP-1 cost, and a two-drug combination priced on top of tirzepatide (annual list price near $13,000) faces a harder access fight. The IP picture matters here: tirzepatide's US composition-of-matter patent runs to November 2036 with follow-on patents to 2041, so macupatide and eloralintide give Lilly a potential post-2036 metabolic franchise with fresh exclusivity if the combination holds up in Phase 3 [10].

Worth watching. The signal to track is the first Phase 2 topline from NCT07215559 or NCT07589608, likely 2026 to 2027 [2][3]. Specific data points that matter: macupatide monotherapy weight loss at 26 to 52 weeks (there is no approved standalone GIPR agonist, so this is a true first-in-class readout), combination weight loss with eloralintide versus tirzepatide monotherapy (needs to show at least 3 to 5 percentage points of additive weight loss to justify the combination over tirzepatide alone), and GI tolerability relative to tirzepatide. Lilly's metabolic franchise generated more than $16B from tirzepatide alone in 2024, so macupatide plus eloralintide's commercial relevance depends on whether it extends the obesity moat into post-tirzepatide patients and bridges past the 2036 patent cliff [6][10]. The CagriSema REDEFINE-1 readout (22.7% weight loss at 68 weeks, below Street expectations near 25%) is a cautionary data point for combination therapies but does not directly read across mechanistically, because CagriSema is amylin plus GLP-1 while macupatide plus eloralintide is GIP plus amylin [7]. Petrelintide's monotherapy performance (around 10% weight loss with clean tolerability) sets the amylin bar for eloralintide and therefore gates the combination narrative [9]. The investor question Lilly has not publicly answered: why run macupatide plus eloralintide rather than tirzepatide plus eloralintide? The likely answer is IP runway and dose-ratio flexibility, but confirmation will have to come from Lilly's R&D commentary. Check back after any Phase 2 topline announcement, which Lilly typically discloses through an 8-K filing or quarterly earnings call. The master protocol structure (NCT06143956) also means Lilly can accelerate or kill arms quickly, so watch 8-K filings for intervention-specific updates [4][5].